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Abstract
 
Background.
 
The likelihood of restenosis is
a major limitation of coronary angioplasty. We studied
whether hirudin, a highly selective inhibitor of thrombin
with irreversible effects, would prevent restenosis after
angioplasty. We compared two regimens of recombinant
hirudin with heparin.
 
Methods.
 
We randomly assigned 1141 patients with
unstable angina who were scheduled for angioplasty to
receive one of three treatments: (1) a bolus dose of
10,000 IU of heparin followed by an intravenous infusion
of heparin for 24 hours and subcutaneous placebo twice
daily for three days (382 patients), (2) a bolus dose of 40
mg of hirudin followed by an intravenous infusion of hiru-
din for 24 hours and subcutaneous placebo twice daily for
three days (381 patients), or (3) the same hirudin regimen
except that 40 mg of hirudin was given subcutaneously in-
stead of placebo twice daily for three days (378 patients).
The primary end point was event-free survival at seven
months. Other end points were early cardiac events (with-
in 96 hours), bleeding and other complications of the
study treatment, and angiographic measurements of cor-
onary diameter at six months of follow-up.
 
Results.
 
At seven months, event-free survival was
67.3 percent in the group receiving heparin, 63.5 percent
in the group receiving intravenous hirudin, and 68.0 per-
cent in the group receiving both intravenous and subcu-
taneous hirudin (P
 

 
0.61). However, the administration of
hirudin was associated with a significant reduction in early
cardiac events, which occurred in 11.0, 7.9, and 5.6 per-
cent of patients in the respective groups (combined rela-
tive risk with hirudin, 0.61; 95 percent confidence interval,
0.41 to 0.90; P
 

 
0.023). The mean minimal luminal diam-
eters in the respective groups on follow-up angiography
at six months were 1.54, 1.47, and 1.56 mm (P
 

 
0.08).
 
Conclusions.
 
Although significantly fewer early cardi-
ac events occurred with hirudin than with heparin, hirudin
had no apparent benefit with longer-term follow-up. (N Engl
J Med 1995;333:757-63.)
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LATELET aggregation, the generation of throm-
bin, and the release of growth factors at the site of
angioplasty have all been implicated in the process of
restenosis.
 
1,2
 
 Consequently, anticoagulants, antiplatelet
agents, and specific antithrombin agents have been con-
sidered for the prevention of restenosis.
 
3
 
 Thrombin
is the most potent platelet activator known, stimulating
the production of platelet-derived growth factor and
the secretion of prostacyclin, platelet-activating factor,
and plasminogen-activator inhibitor. Thrombin has ap-
parent mitogenic effects on lymphocytes and vascular
smooth-muscle cells.
 
4,5
 
Hirudin, a 65-amino-acid compound originally ex-
tracted from the salivary gland of the leech, is a specif-
ic inhibitor of thrombin. The advantage of hirudin over
other serine protease inhibitors is its potency in irre-
versibly blocking thrombin at multiple sites without the
need for circulating antithrombin III.
 
6
 
 Because of the
small size of the hirudin molecule, this substance can
inhibit clot-bound thrombin and restrict the further
formation of thrombus.
 
7
 
Hirudin has reduced the deposition of platelets after
vascular injury in pigs
 
8
 
 and lowered the rate of reste-
nosis in hypercholesterolemic rabbits,
 
9
 
 providing a ra-
tionale for its use in patients undergoing angioplasty. In
this trial we evaluated whether the inhibition of throm-
bin with hirudin as compared with heparin improved
event-free survival in patients undergoing coronary an-
gioplasty.
 
M
 
ETHODS
 
Study Population
 
Patients with unstable angina and one or more clinically important
new or restenotic coronary narrowings suitable for treatment with
percutaneous transluminal coronary angioplasty were eligible for the
study. From September 1992 through May 1993, 1154 patients from
various institutions (listed in the Appendix) were randomized. All
had unstable angina, as defined by the new onset of angina pectoris
or the worsening of angina (i.e., their condition changed by two or
more classes according to the classification system of the Canadian
Cardiovascular Society
 
10
 
 or they needed additional antianginal med-
ication), angina at rest, or both in the preceding three months.
 
11
 
 The
criteria for exclusion from the study were stable angina, a planned
multistage angioplasty procedure or stent implantation, myocardial
infarction occurring within the preceding two weeks, hypertension,
diabetic retinopathy, and body weight over 100 kg.
The study was conducted in accordance with the principles of the
Declaration of Helsinki and its subsequent amendments and with the
laws and regulations of the countries where the trial took place. Be-
fore randomization, each patient gave written informed consent.
 
Antithrombin Regimens
 
The patients were randomly assigned in a double-blind fashion to
receive recombinant hirudin (Revasc, Ciba–Geigy, Basel, Switzer-
land
 
12
 
) in one of two dose regimens or to receive unfractionated so-
dium heparin. The randomization was stratified according to whether
heparin had been administered in the preceding 24 hours. Heparin
therapy had to be discontinued at least 30 minutes before the start
of treatment with the study medication.
The patients received one of the following three treatments: hepa-
rin (an intravenous bolus injection of 10,000 IU of heparin followed
by a continuous intravenous infusion of 15 IU of heparin per kilogram
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of body weight per hour for 24 hours, with placebo given subcutane-
ously twice daily for three consecutive days), intravenous hirudin (an
intravenous bolus injection of 40 mg of hirudin followed by a contin-
uous intravenous infusion of 0.2 mg of hirudin per kilogram per hour
for 24 hours, with placebo given subcutaneously twice daily for three
consecutive days), or intravenous and subcutaneous hirudin (an intra-
venous bolus injection of 40 mg of hirudin followed by a continuous
intravenous infusion of 0.2 mg of hirudin per kilogram per hour for
24 hours, with 40 mg of hirudin given subcutaneously twice daily for
three consecutive days). If the angioplasty lasted more than one hour,
an additional bolus dose of 5000 IU of heparin could be administered
at the option of the physician to the patients in the heparin group, or
an equivalent amount of placebo could be given to the patients in the
hirudin groups. The operators remained blinded to the results of clot-
ting studies, and no adjustment of the rate of infusion of the study
medication was allowed. A concomitant dose of aspirin (100 to 500
mg once daily) was given on the day of angioplasty, and this treat-
ment was continued for at least 14 days.
 
Criteria for Evaluation
 
Efficacy
 
The primary end point was event-free survival 30 weeks after an-
gioplasty — that is, the absence of death, nonfatal myocardial infarc-
tion, coronary-artery bypass grafting or the use of a “bailout” proce-
dure (e.g., stenting), or second angioplasty at previously dilated sites.
Myocardial infarction was diagnosed on the basis of new Q waves
(according to the Minnesota Code
 
13
 
) or an increase in the serum cre-
atine kinase level to more than twice the upper limit of the normal
range, with a concomitant increase in the MB fraction. If a stent was
implanted electively after the initial angioplasty (i.e., not as part of a
bailout procedure), the implantation was considered equivalent to a
second angioplasty. Second angioplasty or bypass surgery needed to
be preceded by typical anginal symptoms or, if there were atypical
anginal symptoms, by electrocardiographic evidence of myocardial
ischemia at rest or during exercise and an angiographically deter-
mined stenosis greater than 50 percent by visual inspection.
Secondary end points were as follows: any of a ranked series of clin-
ical events that included death from cardiac causes, nonfatal myocar-
dial infarction, coronary-artery bypass grafting (or the use of a bail-
out procedure), second angioplasty, and anginal status (according to
the classification system of the Canadian Cardiovascular Society
 
10
 
) at
the 30-week follow-up evaluation; the occurrence of any of these
events within 96 hours after the start of the study medication; the
minimal luminal diameter of the dilated sites as measured by quanti-
tative coronary angiography at the 26-week follow-up evaluation; and
any change in the minimal luminal diameter of dilated sites from im-
mediately after angioplasty to follow-up angiography at 26 weeks.
 
Safety
 
Safety was evaluated with regard to bleeding and other complica-
tions. Bleeding was classified as major if it was overt and led to a de-
crease in the hemoglobin level by at least 2 g per deciliter; if it neces-
sitated the transfusion of two or more units of whole blood or packed
cells; or if it occurred intracranially, retroperitoneally, or at the site
of a major joint.
 
14
 
 Minor bleeding was defined as overt bleeding that
did not meet these criteria.
 
Angiography and Assessment of Coagulation
 
For each patient, coronary angiograms were obtained in a stand-
ardized fashion immediately before and immediately after angioplas-
ty, and at the six-month follow-up evaluation. The angiograms were
analyzed in a core laboratory with the Cardiovascular Angiography
Analysis System.
 
15,16
 
Blood samples for the measurement of coagulation were obtained
at regular intervals before and after angioplasty. Blood samples for
the determination of activated partial-thromboplastin times and lev-
els of prothrombin fragment F
 
1
 

 
2
 
 (a measure of the generation of
thrombin) were obtained separately by atraumatic venipuncture and
were analyzed in a central laboratory.
 
Statistical Analysis
 
Outcomes were compared in an intention-to-treat analysis, which
included all randomized patients in whom coronary angioplasty was
attempted. Patients in whom no angioplasty was attempted (i.e.,
those whose indication for angioplasty changed or disappeared) were
excluded from the analysis. A successful procedure was defined as
one in which the stenosis was reduced by more than half; in the case
of a failed recanalization of a total occlusion, the second lesion treat-
ed was considered to be the first site of angioplasty.
The distribution of event-free survival at 30 weeks was calculated
according to the method of Kaplan and Meier, and distributions were
compared by the Kruskal–Wallis test
 
17
 
; for patients with multiple
events, the first event was considered. Event rates and rates of bleed-
ing and other complications were compared by the chi-square test.
A linear logistic-regression analysis for ordered categories was per-
formed for the ranked clinical outcomes, with pretreatment with hep-
arin used as a covariate. The most severe event in each patient was
considered in the analysis.
The minimal luminal diameters at the dilated sites 26 weeks after
angioplasty were compared by analysis of variance, with the mean
value for all sites used in cases of angioplasty at multiple sites. All
reported P values are two-tailed. Whenever possible, estimates of the
magnitude of the treatment effect are provided, with corresponding
95 percent confidence intervals. Relative risks are presented for the
combined hirudin groups as compared with the heparin group.
 
R
 
ESULTS
 
Study Population
 
A total of 1154 patients were randomized. Of 5686
patients screened, 21 percent were ineligible because
they had stable angina, 16 percent for reasons involv-
ing logistics, and 11 percent because they had had my-
ocardial infarctions during the previous two weeks.
The remaining screened patients (32 percent) were ex-
cluded for a wide variety of reasons. Thirteen patients
 
*Plus–minus values are means 
 

 
SD. Except as noted, all other values are numbers of pa-
tients followed in parentheses by the percentage of the group.
†MI denotes myocardial infarction, CABG coronary-artery bypass graft surgery, CCS Cana-
dian Cardiovascular Society, IV intravenous, RCA right coronary artery, LAD left anterior de-
scending coronary artery, LCX left circumflex coronary artery, and LM left main coronary artery.
 
Table 1. Base-Line Characteristics of the Study Patients Accord-
ing to Group Assignment.
 
*
 
C
 
HARACTERISTIC
 
†
H
 
EPARIN
 
(N
 

 
382)
I
 
NTRAVENOUS
 
H
 
IRUDIN
 
(N
 

 
381)
I
 
NTRAVENOUS
 
 
 
AND
 
S
 
UBCUTANEOUS
 
H
 
IRUDIN
 
 
(N
 

 
378)
 
Male sex 299 (78.3) 300 (78.7) 297 (78.6)
Age (yr) 58.2
 

 
8.7 58.7
 

 
9.1 58.8
 

 
8.9
Weight (kg) 76.0
 

 
10.9 75.9
 

 
11.1 76.7
 

 
10.7
Smoker 104 (27.2) 90 (23.6) 84 (22.2)
Diabetes 44 (11.5) 42 (11.0) 40 (10.6)
Previous MI 148 (38.7) 152 (39.9) 154 (40.7)
Previous CABG 10 (2.6) 8 (2.1) 20 (5.3)
Previous angioplasty 69 (18.1) 69 (18.1) 64 (16.9)
Braunwald class
I 131 (34.3) 146 (38.3) 139 (36.8)
II 163 (42.7) 160 (42.0) 166 (43.9)
III 88 (23.0) 75 (19.7) 73 (19.3)
Exertional angina —
CCS class
1 7 (1.8) 10 (2.6) 6 (1.6)
2 82 (21.5) 69 (18.1) 66 (17.5)
3 144 (37.7) 163 (42.8) 171 (45.2)
4 102 (26.7) 96 (25.2) 89 (23.5)
IV heparin used at screening 115 (30.1) 110 (28.9) 109 (28.8)
Lesions
Total no. 482 483 462
Mean no. per patient 1.26 1.27 1.22
Location before angioplasty
RCA 148 (30.7) 136 (28.2) 139 (30.1)
LAD 230 (47.7) 238 (49.2) 201 (54.5)
LCX 104 (21.6) 109 (22.6) 121 (26.2)
LM 0 0 1 (0.2)
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were not included in the intention-to-treat analysis be-
cause no angioplasty was attempted. Among the re-
maining 1141 patients in whom angioplasty was at-
tempted, 382 were randomly assigned to heparin, 381
to intravenous hirudin, and 378 to intravenous and sub-
cutaneous hirudin. Angioplasty was successful in 91.7
percent, and the results of angiographic follow-up were
available for 86.4 percent. Clinical follow-up was com-
plete for all but one patient.
The clinical and angiographic characteristics of the
patients at base line are shown in Table 1. The charac-
teristics of the three groups were similar. Almost one
third of the patients received intravenous heparin be-
fore randomization because of the severity of their un-
stable angina.
 
Efficacy
 
Among the study patients, 125 patients assigned
to heparin, 139 assigned to intravenous hirudin, and
121 assigned to intravenous and subcutaneous hirudin
reached a primary end point. The distribution of pa-
tients free of events is shown in Figure 1. No significant
differences were observed among the treatment groups
(P
 

 
0.61 by the Kruskal–Wallis test), even after strat-
ification according to pretreatment with heparin.
The incidence of clinical events and angina at 30
weeks is shown in Table 2, with no significant differenc-
es among the three groups (P
 

 
0.61). An analysis of
subgroups according to whether patients were pretreat-
ed with heparin yielded similar results.
The incidence of early events (those occurring in the
first 96 hours after angioplasty) is also shown in Table
2. Forty-two patients assigned to heparin, 30 patients
assigned to intravenous hirudin, and 21 patients as-
signed to intravenous and subcutaneous hirudin had
such events (relative risk in the combined hirudin
groups, 0.61; 95 percent confidence interval, 0.41 to
0.90; P
 

 
0.023). Among the patients pretreated with
heparin, there were 20, 7, and 7 events, respectively
(combined relative risk with hirudin, 0.37; 95 percent
confidence interval, 0.19 to 0.70; P
 

 
0.007). Because
these results suggested a particular benefit of hirudin in
the most unstable patients (those with Braunwald class
III angina), an additional analysis was performed of
the 236 patients who had angina at rest during the 48
hours before randomization. The event rate among
these patients was 21.6 percent in the heparin group,
as compared with 5.3 percent among patients receiving
intravenous hirudin and 12.3 percent among patients
receiving intravenous and subcutaneous hirudin (com-
bined relative risk with hirudin, 0.41; 95 percent confi-
dence interval, 0.21 to 0.78; P
 

 
0.006).
The imbalance in the number of deaths (Table 2)
calls for a description of their exact causes. In the hep-
arin group, three myocardial infarctions and one non-
hemorrhagic cerebrovascular accident resulted in death.
In the group receiving intravenous hirudin, there was
one sudden death. In the group receiving intravenous
and subcutaneous hirudin, five patients had fatal myo-
cardial infarctions. In this group there were also two
cerebrovascular accidents (one of which was hemor-
rhagic), one episode of cardiac tamponade, and one
sudden death; one patient died of respiratory insuffi-
ciency, and one of wound infection and sepsis after by-
pass surgery.
Linear logistic-regression analysis of ordered cate-
gorical data revealed that pretreatment with heparin
 
Figure 1. Kaplan–Meier Distribution of Patients without Events in
the Intention-to-Treat Analysis (N
 

 
1141).
The groups were compared by the Kruskal–Wallis test.
Pr
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*At 96 hours, the combined relative risk in the hirudin groups as compared with the heparin group was 0.61 (95 percent confidence interval, 0.41 to 0.90; P
 

 
0.023).
 
Table 2. Clinical Events in the First 96 Hours and the First 30 Weeks in the Intention-to-Treat Analysis.
 
*
 
E
 
VENT
 
H
 
EPARIN
 
 (N
 

 
382) I
 
NTRAVENOUS
 
 H
 
IRUDIN
 
 (N
 

 
381)
I
 
NTRAVENOUS
 
 
 
AND
 
 S
 
UBCUTANEOUS
 
H
 
IRUDIN
 
 (N
 

 
378)
96 
 
HR
 
30 
 
WK
 
96 
 
HR
 
30 
 
WK
 
96 
 
HR
 
30 
 
WK
 
number (percent)
 
Death 2 (0.5) 4 (1.0) 0 1 (0.3) 0 11 (2.9)
Myocardial infarction 16 (4.2) 20 (5.2) 13 (3.4) 19 (5.0) 9 (2.4) 23 (6.1)
Coronary bypass surgery 9 (2.4)  21 (5.5) 6 (1.6) 21 (5.5) 3 (0.8) 25 (6.6)
Bailout procedure 18 (4.7) 18 (4.7) 12 (3.1) 12 (3.1) 8 (2.1) 8 (2.1)
Second angioplasty 13 (3.4) 91 (23.8) 7 (1.8) 109 (28.6) 5 (1.3) 93 (24.6)
Any event 42 (11.0) 125 (32.7) 30 (7.9) 139 (36.5) 21 (5.6) 121 (32.0)
Any exertional angina — 55 (14.4) — 71 (18.6) — 71 (18.8)
No events or symptoms — 202 (52.9) — 171 (44.9) — 186 (49.2)
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was significantly associated with worse clinical outcomes
at seven months (P
 

 
0.03). The type of study medica-
tion did not influence outcome in this model.
Base-line angiographic measurements and gains in
luminal diameter achieved by angioplasty were similar
in the three groups (Table 3). The changes in minimal
luminal diameter from immediately after angioplasty to
follow-up were also similar (Fig. 2).
 
Safety
 
The incidence of bleeding complications is shown in
Table 4. No differences with respect to major or minor
bleeding were observed among groups. There were
three cerebrovascular accidents. One patient receiving
intravenous and subcutaneous hirudin was readmitted
to the hospital with hemiplegia 14 hours after the final
subcutaneous injection; despite surgical evacuation of
the intracerebral hematoma causing the condition, the
patient died six days after the start of the study treat-
ment. Two intracerebral thrombotic events were ob-
served. One patient (receiving intravenous and sub-
cutaneous hirudin), who presented with symptoms of
neurologic deficit one day after discharge from the hos-
pital and who had multiple brain infarctions on com-
puted axial tomography, died five days after the start of
the study treatment. Another patient (in the heparin
group) presented with massive pulmonary embolism.
Paradoxical embolization through a patent foramen
ovale caused an extensive, expanding cerebral infarc-
tion and led to the patient’s death eight days after the
start of the study medication.
 
Anticoagulant Effects
 
Levels of prothrombin fragment F
 
1
 

 
2
 
 are shown in
Figure 3. The median levels peaked in both hirudin
groups at the end of the procedure (from 1.1 nmol per
liter at the time of screening to 1.4 nmol per liter in the
group receiving intravenous hirudin, and from 1.0 to
1.3 nmol per liter in the group receiving intravenous
and subcutaneous hirudin), whereas in the heparin
group the levels were slightly reduced (to 0.9 nmol per
liter) as compared with those at the time of screening
(1.0 nmol per liter). Levels of prothrombin fragment
F
 
1
 

 
2
 
 measured at 24, 96, and 98 hours subsequently re-
turned to the base-line values in all three groups.
Measurements of activated partial-thromboplastin
time (Fig. 3) were higher at the end of the procedure
in the subjects receiving heparin than in those receiv-
ing hirudin, an effect that disappeared after 24 hours.
The infusion of hirudin resulted in a more stable ef-
fect. Slightly prolonged activated partial-thromboplas-
tin times were observed at 96 hours after angioplasty
in the group receiving intravenous and subcutaneous
hirudin.
 
D
 
ISCUSSION
 
Although hirudin was associated with impressive re-
ductions in the rate of major cardiac events in the first
96 hours after angioplasty as compared with heparin,
the primary goal of this trial, a reduction in the rate of
cardiac events at seven months, was not accomplished.
Event-free survival at seven months did not differ among
the treatment groups.
At least three other trials using specific antiplatelet
drugs have demonstrated beneficial effects on the acute
complications of coronary angioplasty without favor-
ably influencing long-term clinical outcomes.
 
18-20
 
 These
findings differ from the results of the Evaluation of 7E3
for the Prevention of Ischemic Complications (EPIC)
trial,
 
21,22
 
 in which the glycoprotein IIb/IIIa receptor was
presumed to have been blocked completely and which
showed a reduction in early cardiac events that was
maintained with longer-term follow-up.
The dosage and duration of treatment in the present
trial were chosen as a compromise among safety issues,
logistic considerations, and the scientific evidence avail-
able when the trial was designed. Primarily, the dosage
was based on safety data obtained in healthy volun-
teers, stable patients undergoing angioplasty, and pa-
tients undergoing orthopedic surgery.
 
23-25
 
 However, the
results of assays of prothrombin fragment F
 
1
 

 
2
 
 imme-
diately after angioplasty suggest that the generation of
thrombin was not satisfactorily inhibited in either hiru-
din group, whereas the dosage of heparin we used re-
sulted in an appropriate decrease in levels of prothrom-
 
*As estimated by computer techniques on the basis of the diameters of segments proximal
and distal to the site of stenosis.
 
Table 3. Mean (
 

 
SD) Angiographic Measurements in the Inten-
tion-to-Treat Analysis of Patients for Whom Follow-up Data Were
Available.
 
V
 
ARIABLE
 
H
 
EPARIN
 
(N
 

 
330)
I
 
NTRAVENOUS
 
 
H
 
IRUDIN
 
(N
 
 341)
INTRAVENOUS 
AND
SUBCUTANEOUS
HIRUDIN
(N  315)
millimeters
Reference luminal diameter* 2.690.51 2.670.51 2.700.51
Minimal luminal diameter
Before angioplasty 0.990.38 0.970.39 1.030.35
After angioplasty 1.800.37 1.780.36 1.820.37
At follow-up 1.540.59 1.470.56 1.560.50
Gain 0.810.41 0.820.44 0.790.41
Loss 0.260.52 0.320.50 0.260.45
Figure 2. Cumulative Distribution of the Reduction in Minimal Lu-
minal Diameter from Immediately after Angioplasty to Follow-up
at Seven Months.
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bin fragment F12 at six hours. It can be inferred from
these data that the adjustment in the infusion rate —
from 0.16 mg per kilogram per hour in the pilot study
of patients with stable angina25 to 0.20 mg per kilo-
gram per hour in the current trial of patients with un-
stable angina and presumably higher levels of throm-
bin generation — was too cautious a change in dosage.
Zoldhelyi et al.26 recently reported failing to block the
generation of thrombin in their patients despite the
presence of a 10,000-fold molar excess of free hirudin
over the amount bound in complexes with thrombin.
Infusion rates of hirudin in experiments with animals
were as much as five times higher than those currently
used, a finding that may explain the lack of a long-term
effect in the present study.8,9
When hirudin was administered subcutaneously in
healthy volunteers at a dose of 0.5 mg per kilogram
twice daily, the activated partial-thromboplastin time
12 hours after the first injection was subtherapeutic,23
and it may be inferred that the inhibition of the conver-
sion of prothrombin was also inadequate in the first
three days of the trial. A putative explanation for the
apparent paradox by which the early outcome is im-
proved although there is less appropriate control of
thrombin may be that the dosage used was not suffi-
cient to produce an adequate level of anticoagulation,
but was sufficient to limit the thrombin-mediated ag-
gregation and activation of platelets, causing effects sim-
ilar to those observed over the short term in the EPIC
trial.8,21,22
The optimal duration of treatment is unknown, even
in animal models. Conflicting findings about the time
course of thrombogenicity in the injured vessel wall
have been reported.27-30 In this study we decided to
maintain our patients at effective levels of antithrombin
activity as long as possible. Since ethical considerations
necessitated monitoring the patients’ safety in the hos-
pital during the subcutaneous injections of hirudin, a
reasonable compromise between the duration of hiru-
din administration and logistic considerations of the
trial was presumably achieved by administering the
Table 4. Bleeding Complications.
COMPLICATION
HEPARIN
(N  382)
INTRAVENOUS
HIRUDIN (N  381)
INTRAVENOUS AND
SUBCUTANEOUS
HIRUDIN 
(N  378)
number (percent) of patients
Major bleeding
Overt, with decrease in hemo-
globin by 2 g/dl
24 (6.2) 18 (4.7) 28 (7.4)
Overt, requiring transfusion 
of 2 units whole blood 
or packed cells
0 3 (0.8) 0 
Intracranial 0 0 1 (0.3)
Retroperitoneal or in a 
major joint
0 0 0 
All 24 (6.2) 21 (5.5) 29 (7.7)
Minor bleeding 43 (11.3) 50 (13.1) 57 (15.1)
Figure 3. Levels of Prothrombin Fragment F12 and Activated Partial-Thromboplastin Times in the Three Study Groups at Various
Times before and after Angioplasty.
A denotes the group receiving heparin, B the group receiving intravenous hirudin, and C the group receiving intravenous and subcu-
taneous hirudin. The solid area inside each box indicates the median value, and the left and right margins of the box indicate the
upper limits of the first and third quartiles, respectively.
In the left-hand panel, the dotted vertical line indicates the upper limit of the normal level of prothrombin fragment F12 (1.4 nmol per
liter). Heparin tended to control the generation of thrombin better than hirudin both immediately after angioplasty and six hours after
the start of the infusion.
In the right-hand panel, the activated partial-thromboplastin time was measured up to a maximum of 150 seconds. Over the first 24
hours this value was more than double the base-line value in the hirudin-treated groups, whereas in the heparin-treated group it re-
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turned almost to the base-line level.
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drug intravenously for 24 hours and subcutaneously for
three consecutive days.
A clearly beneficial effect of hirudin on platelet ag-
gregation and thrombus formation was indicated by
the prevention of acute ischemic events early after an-
gioplasty. The failure of hirudin in this trial to alter
longer-term outcomes indicates either that thrombin
generation and thrombus formation in the period im-
mediately after angioplasty may be less important in
the process of restenosis than was previously believed
or that complete reversal of the thrombogenicity of the
injured vessel wall was not achieved or requires more
time. Whether the large decrease in major events ob-
served with hirudin early after the infusion can be
translated to an improved long-term outcome with pro-
longed subcutaneous administration of hirudin deserves
further study.
We are indebted to David P. Foley, M.D., and Peter N. Ruygrok,
M.D., for their criticisms and comments, and to Wanda H. Wentow-
ski for her expert assistance in the preparation of the manuscript.
APPENDIX
The following institutions and investigators participated in the
Helvetica (Hirudin in a European Trial versus Heparin in the Pre-
vention of Restenosis after PTCA) trial. The number of patients en-
rolled at each center is given in parentheses, followed by an asterisk
when all patients in the cardiac catheterization laboratory at a center
were screened and the results entered in a logbook.
Medizinische Klinik III, Heidelberg, Germany (66)* — C. Bode,
G. Schuler, S. Abed, H. Baumann; Universitätsklinik Rudolf Vir-
chow, Berlin (66)* — W. Rutsch, C. Brunckhurst, N. Kokott; Medi-
zinische Universitätsklinik, Kiel, Germany (66)* — R. Simon,
M. Lins, G. Herrmann; Onze Lieve Vrouwe Gasthuis, Amsterdam
(60)* — G. J. Laarman, F. Kiemeneij, H. Swart; Medisch Centrum
de Klokkenberg, Breda, the Netherlands (54)* — A. van den Bos,
M. Quarles van Ufford, U. Chin-Kon-Sung, G. Uytdehaag; Acade-
misch Ziekenhuis Groningen, Groningen, the Netherlands (54) —
R. van Dijk, P. Den Heyer, L. Drok, J. Klein; Istituto Apparato Car-
diovascolare, Bologna, Italy (54)* — A. Marzocchi, G. Piovaccari,
C. Marrozinni, E. Cere; Academisch Ziekenhuis Dijkzigt, Rotter-
dam, the Netherlands (54)* — P. Serruys, P. de Feyter, V. Umans,
J. Herrman; Ospedali Riuniti, Bergamo, Italy (53)* — G. Guag-
liumi, O. Valsecchi, A. Casari, A. Piti’, A. Tasca; Medizinische Uni-
versitätsklinik, Freiburg, Germany (52)* — A. Zeiher, H. Woll-
schläger, V. Schächinger; Hospital General Gregorio Maranon,
Madrid (48)* — J. Delcan Dominguez, E. Garcia, J. Joriano, J. Eliza-
ga; Sahlgrenska Hospital, Göteborg, Sweden (48)* — H. Emanuels-
son, P. Albertsson, P. Hardhammar, L. Ekström; Hospital Clinico
San Carlos, Madrid (48)* — C. Macaya, F. Alfonso, R. Hernandez,
A. Iniguez; CHU Sart Tilman, Liège, Belgium (44)* — V. Legrand,
M. Bellekens, P. Marcelle, P. Doneux; Ospedale di Circolo, Varese,
Italy (36)* — G. Binaghi, S. Repetto, E. Verna, B. Castiglioni; Hos-
pital Marques de Valdecilla, Santander, Spain (30)* — T. Colman,
J. Zueco, A. Figueroa; U.C.L. Saint-Luc, Brussels, Belgium (30)* —
C. Hanet, W. Wijns, J. Cosyns, X. Michel; Ospedale Maggiore, Tri-
este, Italy (30)* — S. Klugmann, E. Della Grazia, L. Barbieri;
Hôpital Universitaire de Mont-Godinne, Yvoir, Belgium (30)* —
E. Schroeder, P. Chenu, D. Grolaux; CHR Nancy, Vandoeuvre-
les-Nancy, France (26)* — N. Danchin, Y. Juilliere, F. Cherrier,
C. Kettani; Onze Lieve Vrouwziekenhuis, Aalst, Belgium (26)* —
G. Heyndrickx, B. de Bruyne, M. Goethals, P. Goemare; Franz Vol-
hard Klinik, Berlin-Buch, Germany (24)* — D. Gulba, G. Claus,
S. Hauck; Centre Cardiologique du Nord, Saint Denis, France (24)*
— M.-C. Morice, T. Royer, B. Glatt, E. Rosenblatt; Ziekenhuis
de Weezenlanden, Zwolle, the Netherlands (24) — F. Zijlstra,
H. Suryapranata, H. Schoenmaker, G. Velsink; Hospital Clinic i
Provincial, Barcelona, Spain (23)* — A. Betriu, A. Serra, G. Sanz,
M. Heras; Catharina Ziekenhuis, Eindhoven, the Netherlands (18)*
— J. Bonnier, N. Pijls, M. el Gamal, S. Rouffel; Ospedale Nuguarda,
Milan, Italy (18)* — L. Campolo; Policlinico San Matteo, Pavia, It-
aly (18)* — G. Specchia, S. de Servi, F. Marisco; Centre Chirurgical
Marie Lannelongue, Les Plessis Robinson, France (15)* — B. Lan-
celin, B. Chevalier, P. Guyon, F. Philippe; CHRU Rouen Hôpital,
Rouen, France (15)* — B. Letac, H. Eltchaninoff, R. Koning,
A. Cribier.
Steering Committee: P.W. Serruys (chairman), A. Betriu, F. Camerini
(Ospedale Maggiore, Trieste, Italy), N. Danchin (Hôpital Brabois,
Vandoeuvre-les-Nancy, France), H. Emanuelsson, W. Rutsch, A. van
den Bos, P. Close, J.W. Deckers, R. Kerry (Pharma Division, Ciba–
Geigy Ltd., Basel, Switzerland), J. Rijnierse (Ciba–Geigy, Arnhem,
the Netherlands), P. Peerboom (Cardialysis, Rotterdam), V. Umans.
Sponsor (Ciba–Geigy, Basel, Switzerland): P. Close, R. Kerry, P. Kobi.
Angiographic Core Laboratory (Cardialysis, Rotterdam): L. Rodenburg,
P.F. Peerboom, E. Nibbering, J. Pameijer, J.P.R. Herrman, V.A.W.M.
Umans, J.W. Deckers. Data Coordinating and Analysis Center: Ciba–Gei-
gy — P. Close, R. Kerry, P. Kobi, D. Bach, E. Grundl; Department of
Clinical Epidemiology and Biostatistics, Cardialysis — R. Melkert.
Hemostasis Core Laboratory (Department of Hemostasis and Thrombo-
sis, Academic Medical Center, Amsterdam) — H. Büller. Safety Com-
mittee: K. Fox (chairman), H. Büller, D. Chamberlain (Royal Sussex
County Hospital, Brighton, United Kingdom), Z. Pelikan (Medisch
Centrum de Klokkenberg, Breda, the Netherlands), J. Tijssen (Aca-
demic Medical Center, Amsterdam). Critical Events Committee:
H. Schmutzler (chairman) (Universitätsklinik Rudolf Virchow, Ber-
lin), G. Heyndrickx, A. Zeiher, G. Specchia. Angiography Committee:
R. Simon (chairman), V. Legrand, G. J. Laarman, H. Suryapranata.
Study directors: J.W. Deckers, P. Close.
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